375 related articles for article (PubMed ID: 29550418)
1. SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas.
Kim AL; Back JH; Chaudhary SC; Zhu Y; Athar M; Bickers DR
J Invest Dermatol; 2018 Aug; 138(8):1716-1725. PubMed ID: 29550418
[TBL] [Abstract][Full Text] [Related]
2. MTOR promotes basal cell carcinoma growth through atypical PKC.
Chow RY; Levee TM; Kaur G; Cedeno DP; Doan LT; Atwood SX
Exp Dermatol; 2021 Mar; 30(3):358-366. PubMed ID: 33617094
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
5. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
6. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
7. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
8. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.
Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C
Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799
[TBL] [Abstract][Full Text] [Related]
9. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.
Bakshi A; Chaudhary SC; Rana M; Elmets CA; Athar M
Mol Carcinog; 2017 Dec; 56(12):2543-2557. PubMed ID: 28574612
[TBL] [Abstract][Full Text] [Related]
10. Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma.
Deng M; Marsch AF; Petronic-Rosic V
Skinmed; 2017; 15(4):265-268. PubMed ID: 28859735
[TBL] [Abstract][Full Text] [Related]
11. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition.
Jussila AR; Haensel D; Gaddam S; Oro AE
J Invest Dermatol; 2024 Jun; 144(6):1368-1377.e6. PubMed ID: 38157930
[TBL] [Abstract][Full Text] [Related]
13. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.
Albert B; Hahn H
Adv Exp Med Biol; 2014; 810():329-41. PubMed ID: 25207374
[TBL] [Abstract][Full Text] [Related]
14. Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: an update.
Reichrath J; Rass K
Adv Exp Med Biol; 2014; 810():208-33. PubMed ID: 25207368
[TBL] [Abstract][Full Text] [Related]
15. Hair follicle disruption facilitates pathogenesis to UVB-induced cutaneous inflammation and basal cell carcinoma development in Ptch(+/-) mice.
Xu J; Weng Z; Arumugam A; Tang X; Chaudhary SC; Li C; Christiano AM; Elmets CA; Bickers DR; Athar M
Am J Pathol; 2014 May; 184(5):1529-40. PubMed ID: 24631180
[TBL] [Abstract][Full Text] [Related]
16. AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.
Kim AL; Back JH; Zhu Y; Tang X; Yardley NP; Kim KJ; Athar M; Bickers DR
Cancer Prev Res (Phila); 2016 Oct; 9(10):794-802. PubMed ID: 27388747
[TBL] [Abstract][Full Text] [Related]
17. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
18. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
[TBL] [Abstract][Full Text] [Related]
19. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
[TBL] [Abstract][Full Text] [Related]
20. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
